2022
Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke
Zhou LW, Kraler L, de Havenon A, Lansberg MG. Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. Journal Of The American Heart Association 2022, 11: e024992. PMID: 35656996, PMCID: PMC9238703, DOI: 10.1161/jaha.121.024992.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth care costsHigher quality-adjusted life yearsNet monetary benefitLifetime quality-adjusted life yearsProbabilistic sensitivity analysesCare costsMonetary benefitsSensitivity analysisLife yearsCost inputsLifetime costsLower health care costsCost savingsCostBest available dataWillingnessSavingsMonte Carlo simulationsTreatment effectsCarlo simulationsAvailable dataBenefitsDecision tree
2021
Cilostazol for Secondary Stroke Prevention
de Havenon A, Sheth KN, Madsen TE, Johnston KC, Turan TN, Toyoda K, Elm JJ, Wardlaw JM, Johnston SC, Williams OA, Shoamanesh A, Lansberg MG. Cilostazol for Secondary Stroke Prevention. Stroke 2021, 52: e635-e645. PMID: 34517768, PMCID: PMC8478840, DOI: 10.1161/strokeaha.121.035002.Peer-Reviewed Original ResearchConceptsSecondary stroke preventionStroke preventionDouble-blind placebo-controlled randomized trialLargest secondary stroke prevention trialSecondary stroke prevention trialsPlacebo-controlled randomized trialStroke Prevention TrialTreatment of claudicationOpen-label designNoncardioembolic ischemic strokePeripheral arterial diseaseLong-term treatmentOnset of benefitDays of treatmentEuropean Medicines AgencyCognitive outcome dataMillions of patientsPremature trial terminationDrug discontinuationMajor bleedingGastrointestinal symptomsStroke recurrenceIschemic strokeNoncardioembolic strokeSecondary prevention